European Journal of Medicinal Chemistry p. 231 - 251 (2016)
Update date:2022-08-15
Topics:
Wang, Yang
Cheng, Fei Xiong
Yuan, Xiao Long
Tang, Wen Jian
Shi, Jing Bo
Liao, Chen Zhong
Liu, Xin Hua
It is of our interest to generate and identify novel compounds with regulation telomerase for cancer therapy. In order to carry out more rational design, based on structure-based drug design, several series of N-substituted-dihydropyrazole derivatives, totally 78 compounds as potential human telomerase inhibitors were designed and synthesized. The results demonstrated that some compounds had potent anticancer activity against four tumor cell lines, and showed good selectivity on tumor cells over somatic cells. By the modified TRAP assay, compound 13i exhibited the most potent inhibitory activity against telomerase with an IC50 value of 0.98 μM. In vivo evaluation results indicated that compound 13i could inhibit growth of S180 and HepG2 tumor-bearing mice, and it also significantly enhanced the survival rate of EAC tumor-bearing mice. The further results in vivo confirmed that it could significantly improve pathological changes of N,N-diethylnitrosamine (DEN)-induced rat hepatic tumor. These data support further studies to assess rational design of more efficient telomerase inhibitors in the future.
View MoreChangzhou Sunsheng Chem Co., Ltd
Contact:+1-(989)-854-0648
Address:No. 28 Yinshan Rd., Xixiashu Industrial Park
Quzhou Ruiyuan chemical Co., Ltd
Contact:+86-570-3039321/3039361/3039308
Address:18# Huayang Road,Quzhou High-tech Industrial Park, Zhejiang China.
Beijing Tianjia Chemical Science & Technology Co.,Ltd
Contact:86-0550-2392698
Address:No.388, Shiliang Road (East),
Contact:+86-371-67759225
Address:No.32, Jinsuo Road, High-tech Zone
Contact:+1-973-357-0577
Address:10 Taft Rd.
Doi:10.1021/jo00350a047
(1985)Doi:10.1016/S0040-4020(01)96485-3
(1985)Doi:10.1002/hc.20598
(2010)Doi:10.1021/ja00311a041
(1985)Doi:10.1016/j.ejmech.2003.09.011
(2004)Doi:10.1016/j.bmcl.2004.10.068
(2005)